Plasma 8‐methoxypsoralen concentrations in photochemotherapy of psoriasis

A quantitative study of 8‐methoxypsoralen plasma profiles in patients with psoriasis undergoing photochemotherapy shows that a poor response to the treatment may be explained in terms of abnormal pharmacokinetic behaviour. However, not all ‘poor responders’ exhibit an abnormal pattern and for these an alternative explanation is required.

[1]  G. Plewig,et al.  8‐MOP plasma levels in PUVA problem cases with psoriasis , 1979, The British journal of dermatology.

[2]  C. Hensby.  The qualitative and quantitative analysis of 8‐methoxypsoralen by HPLC‐UV and GLC‐MS , 1978, Clinical and experimental dermatology.

[3]  J. Parrish,et al.  Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. , 1977, The Journal of investigative dermatology.

[4]  W. Frain-Bell,et al.  Photochemotherapy in the treatment of psoriasis , 1977, The British journal of dermatology.

[5]  A. Kligman,et al.  Ineffectiveness of trioxsalen as an oral photosensitizer. , 1973, Archives of dermatology.

[6]  B. Mandula,et al.  Metabolic reactions in vitro of psoralens with liver and epidermis. , 1979, Biochemical pharmacology.

[7]  H. Wulf,et al.  Distribution of tritium-labelled 8-methoxypsoralen in the rat, studied by whole body autoradiography. , 1979, Acta dermato-venereologica.

[8]  I. Steiner,et al.  Serum levels of 8-methoxypsoralen 2 hours after oral administration. , 1978, Acta dermato-venereologica.

[9]  P. Thune.  Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets. , 1978, Acta dermato-venereologica.

[10]  P. Thune,et al.  Photochemotherapy of psoriasis with relevance to 8-methoxypsoralen plasma level and low intensity irradiation. , 1977, Acta dermato-venereologica.

[11]  W. Reed.  Letter: Treatment of psoriasis with oral psoralens and longwave ultraviolet light. , 1976, Acta dermato-venereologica.